Central Sleep Apnoea (CSA) treatment options | ResMed

Treatment options for central sleep apnoea

It can be challenging to treat patients with CSA, who often experience less or different symptoms than OSA patients. Adaptive servo-ventilation* as delivered by the AirCurve 11 ASV PaceWave is an appropriate choice for treating most of these more complex patients.*

How prevalent is central sleep apnoea?

of ischemic and haemorrhagic stroke and transient ischemic attack patients have primarilycentral apnoeas1

of patients on opioids have central apnoea or combined obstructive and central sleep apnoea2

of heart failure with preserved ejection fraction patients patients have central sleep apnoea2

Central sleep apnoea treatment options

Continuous positive airway pressure or automatic positive airway pressure (CPAP/APAP) therapy is often used as the treatment of first intention, but experience shows that CPAP/APAP does not consistently control apnoeas or improve symptoms. As a result, some patients treated with CPAP/APAP remain symptomatic. This increases the risk of non-compliance and the likelihood that they will require multiple, resource-intensive interventions.

Adaptive servo-ventilation* is always an appropriate choice for treating these more complex patients, either as a first intention therapy or after an unsuccessful trial with other positive airway pressure (PAP) therapies.

ASV improves outcomes

Recent research, including registries and large cohort studies (READ-ASV, FACE and FACIL-VAA), has shown the positive effects of ASV therapy on the general patient population.3,4,5

Adaptive servo-ventilation: a proven solution for CSA

ASV is a form of PAP therapy that delivers auto-adjusting pressure support with automatic pressure support and expiratory positive airway pressure. ASV helps to treat both obstructive and central respiratory events and maintains adequate ventilation in response to patients’ changing needs.


Compared to other forms of PAP therapy, ASV offers significant benefits for the treatment of central sleep-disordered breathing.* This has been demonstrated in multiple clinical trials across various patient types.

This content is intended for health professionals only.

Please refer to the user guides for relevant information related to any contraindications, warnings and precautions to be considered before and during use of the product. This content is intended for health professionals only.

* ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnoea.

  1. Javaheri S., Smith J., Chung E., The Prevalence and Natural History of Complex Sleep Apnea, Journal of Clinical Sleep Medicine, Vol.5, No. 3, 2009.
  2. Mogri M et al. Hypoxemia in patients on chronic opiate therapy with and without sleep apnea. Sleep Breath, 2009;13:49-57.
  3. Karin G. Johnson and Douglas C. Johnson. Frequency of Sleep Apnea in Stroke and TIA Patients: A Meta-analysis. J Clin Sleep Med, 2010;6(2):131-137 .

Content last updated: 054/2024.